Navigation Links
NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
Date:11/6/2013

LAWRENCE, Mass., Nov. 6, 2013 /PRNewswire/ -- NxStage Medical Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is introducing  three new products at the American Society of Nephrology (ASN) Annual Kidney Week 2013 Meeting in Atlanta, GA November 5 – 10, 2013 at booth #1129. The new offerings include the NxStage System One™ S, Nx2me Connected Health™, and the NxStage Dosing Calculator.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The NxStage System One S's higher dialysate flow rates allow for a wider range of flexible therapy options and a higher dose in the same time as it would take with the System One. The System One S allows nephrologists expanded possibilities to adjust the duration and frequency of patient prescriptions with greater flexibility than they have today.

Nx2me Connected Health leverages tablets, cloud computing and wireless communications. A key component of this solution is the Nx2me™ app, developed for the iPad® and used by patients at home. The app collects NxStage System One cycler data, as well as patient information such as blood pressure and weight. Patients can review, confirm, and transmit this data to their centers after each treatment. Dialysis center staff can access the transmitted data using the Nx2me™ Clinician Portal, gaining enhanced capabilities to review and follow treatment adherence and progress.

The new NxStage Dosing Calculator is an online tool that helps physicians develop prescriptions tailored to patients' clinical and lifestyle objectives. Using formulas from peer-reviewed publications, the Dosing Calculator quickly displays a wide range of therapy options to assist physicians in prescribing for a desired dose. This online tool is designed to reduce nephrologist time in calculating and assessing hundreds of possible prescription options to achieve clinical goals. The NxStage Dosing calculator, which is a free service, can be accessed directly at http://dosingcalculator.nxstage.com

"I'm very proud of our continued commitment to innovation and our ability to bring new products to market," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. "We are really excited about the potential of these enhancements to improve both ease of use of our therapy and efficiency for providers, clinicians, and most importantly, our patients."

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.

About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Kristen K. Sheppard, Esq.
Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
3. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):